On November 12, 2026 EpicentRx reported its CEO Dr. Tony Reid will be at The Connective Tissue Oncology Society 2026 Annual Meeting taking place November 18–21, 2026, in Seoul, South Korea. New clinical data from the Phase 1/2 BETAPRIME trial will be presented in the abstract entitled: ADAPT-001 with a checkpoint inhibitor in angiosarcoma refractory to checkpoint inhibition: activity and durability of response.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, EpicentRx, NOV 12, 2026, View Source [SID1234674672])